Shield Therapeutics Share Discussion Threads

[ny boy] 24/1/2019 19:59

Yes, a good target to aim for later this year, if all pans out accordingly, as they said only delay forvFDA approval, would be down to Government shut down, so if not end of July, could be say another 2-4 weeks later?

[cf456] 24/1/2019 19:30

US approval has got to surely have a very good chance given that Feraccru has already been approved in Europe.

Adding Peel Hunt's 70p target and 85p for the US together gives 155p which is what they must reckon on if US approval is granted later this year.

155p is significant upside from the current 40.7p mid.

[ny boy] 24/1/2019 19:19

Broker Peel Hunt said the expected revenue of £11.9mln for 2018 was in line with its £12mln forecast while the end-of-year cash balance of £9.8mln was better than the £9.6mlnm it had predicted.

“The AEGIS H2H [head-to-head] study remains on track to report results by end March 2019, potentially resulting in a milestone payment from Norgine, amounting to c £2mln if it achieves its primary endpoint of non-inferiority [versus Ferinject, the leading intravenous iron therapy].”

Peel Hunt said its target price of 70p implies more than 100% upside “and includes nothing for the US market”, which Peel Hunt estimates could be worth an additional 85p per share on a partnered basis.

“If FDA approval is received this year, the US market offers further very strong near-term expansion potential for Feraccru,” the broker said.

[cf456] 24/1/2019 17:24

free stock charts from uk.advfn.com

[cf456] 24/1/2019 16:45

Good elevator pitch by the CEO:

[ny boy] 24/1/2019 16:42

Excellent news, been holding for ages, pays to be patient GLA long term holders

[cf456] 24/1/2019 16:34

Liberum Capital has an 80p target on the shares. "With enough cash to fund the business into 2020 and two potentially major share price catalysts in the next six months, Liberum reiterated its 'buy' rating"

"Peel Hunt said its target price of 70p implies more than 100% upside “and includes nothing for the US market”, which Peel Hunt estimates could be worth an additional 85p per share on a partnered basis.

“If FDA approval is received this year, the US market offers further very strong near-term expansion potential for Feraccru,” the broker said."

[cf456] 24/1/2019 16:02

A breakout above 41p on the chart would be significant:

[cf456] 24/1/2019 15:49

CEO interview today:

[ny boy] 24/1/2019 10:28

Good trading update, when they get FDA approval, (late July) the share price will double imo

[ny boy] 23/1/2019 18:18

A lot of buying underway, looking good for a break above 41p soon!

[aim_trader] 21/1/2019 09:37

Shield Therapeutics will be presenting to investors at the Proactive One2One Investor Forum taking place on the evening of Thursday 24th January 2019. For details and registration here:

[ny boy] 17/1/2019 07:56

Chart shows we are approaching 41p resistance, if we can start closing above the level, then clear skies ahead. Stay patient!

[ny boy] 16/1/2019 15:44

Still holding since last year, steady progress, let’s hope for some decent news flow this quarter!

[hsm12] 16/1/2019 14:27

This looks good

[tromso1] 16/1/2019 13:29

Medical expert discusses his experience working with Shield Therapeutics' Feraccru drug

[hsm12] 11/1/2019 14:17

And it's moving!

[hsm12] 11/1/2019 10:00

This must be the only global biotech stock that hasn't moved. Peel Hunt's top

[tomps2] 14/12/2018 14:09

Here's the Shield Therapeutics presentation from Mello, November 2018.



A good overview of what they do, by Tim Watts, CFO.

I was also interested to see they qualify for the Stockopedia R&D Breakthroughs Screen.

[advfn_sales] 21/11/2018 16:34

Here is your chance to meet with Shield Therapeutics:

Using this unique discount code, ADVFN25, you will be able to get £25 off at Mello London 2018, a 2 day investor conference from the 26th – 27th November 2018 at the Clayton Hotel, Chiswick, London.



Tickets are normally priced at £99 for two days and £79 for one.

Type in ADVFN25 as the discount code.

Many Thanks and take advantage of this premium offer.

See you there.

[davidosh] 18/11/2018 23:07

Here is the full two day programme schedule for MelloLondon including Shield Therapeutics



It is jam packed full of about 75 company presentations, lots of top quality speakers and panel sessions plus workshops to help with investment style and techniques etc.

The pre event fun starts on the Sunday evening with a dinner and investor quiz hosted by John Lee but the main conference begins on Monday 26th November at 9am through to Tuesday 27th in the evening so do come and join us as there are still 97 tickets left...



See you there.

[ny boy] 09/11/2018 15:15

Patient investors to be rewarded going into next year me thinks

[spmc] 09/11/2018 14:59

For any one who is interested Evgen Pharma has results of 2 trials due over the next few weeks, share price is starting to rise in anticipation is up 25% already this week. Currently at 17p pre results broker target is £1.10.

[holiday6] 08/11/2018 13:53

Some big crosses today - I wonder if that has settled down the register?

[ny boy] 21/9/2018 07:34

Gap to 115p, should be an exciting few years ahead